My PCR
Create Account
Logo PCR

17 Feb 2024

TAVI

The optimal first valve choice for patients with aortic stenosis - Key considerations for lifetime management

Sponsored by Edwards Lifesciences

Anchorperson: K. Hayashida
Spokesperson: B. Prendergast
SHOW MORE

Summary

This session tackles the pressing topic of TAVI's success in treating aortic stenosis, particularly in younger patients, and the ensuing questions regarding device durability, potential follow-up procedures, and the interplay between TAVI and surgical options. The aim is to ensure optimal decision-making that prioritizes patient welfare and utilizes complementary treatments effectively.

Learning Objectives

  • To learn how the latest TAVI technology optimises valve durability and minimises patient reintervention
  • To learn how the latest device performs in Asian patients
  • To understand the current situation of TAV-in-TAV and the importance of first valve for patient lifetime management
Related Content
How to approach the challenges of large annuli in TAVI Step-by-step TAVI procedure in Europe and India - A review from PCR and India Valves Share your work at PCR-CIT China Chengdu Valves 2025
Recommended for you
ESC Congress 2025: The DOUBLE-CHOICE trial TAVI for pure aortic regurgitation - LIVE case New iterations of self expendable valves - LIVE case